Iron Triangle Partners’s Charles River Laboratories CRL Stock Holding History

Iron Triangle Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$75.7M	Buy	379,728 +111,728	+42%	+$20.3M	8.66%	1
2025 Q3	$41.9M	Sell	268,000 -52,000	-16%	-$8.26M	5.96%	5
2025 Q2	$48.6M	Buy	+320,000	New	+$42.7M	7.46%	2
2023 Q2	–	Sell	-130,000	Closed	-$26.2M	–	24
2023 Q1	$26.2M	Sell	130,000 -70,000	-35%	-$15.9M	3.78%	14
2022 Q4	$43.6M	Sell	200,000 -2,000	-1%	-$437K	7.81%	2
2022 Q3	$39.8M	Buy	+202,000	New	+$43.6M	6.95%	1
2022 Q1	–	Sell	-70,000	Closed	-$26.4M	–	30
2021 Q4	$26.4M	Buy	70,000 +32,596	+87%	+$12.7M	3.68%	15
2021 Q3	$15.4M	Sell	37,404 -110,524	-75%	-$45.9M	2.22%	19
2021 Q2	$54.7M	Buy	147,928 +7,928	+6%	+$2.65M	5.64%	7
2021 Q1	$40.6M	Hold	140,000	–	–	5.16%	7
2020 Q4	$35M	Buy	140,000 +10,000	+8%	+$2.38M	4.53%	8
2020 Q3	$29.4M	Hold	130,000	–	–	6.58%	3
2020 Q2	$22.7M	Buy	130,000 +30,000	+30%	+$4.79M	5.71%	5
2020 Q1	$12.6M	Buy	+100,000	New	+$15M	4.88%	7

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Iron Triangle Partners's CRL Position: Q4 2025 in Review

Iron Triangle Partners increased its Charles River Laboratories (CRL) stake by 42% in Q4 2025, buying an estimated $20.3M and bringing the position to 379,728 shares worth $75.7M. The position accounts for 8.66% of the portfolio, ranked #1.

Iron Triangle Partners first reported a position in CRL in Q1 2020 and has held it in 14 quarters since. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

Iron Triangle Partners held 379,728 shares of Charles River Laboratories worth $75.7M as of Q4 2025.
Iron Triangle Partners bought 111,728 Charles River Laboratories shares in Q4 2025, an estimated $20.3M.
Charles River Laboratories made up 8.66% of Iron Triangle Partners's portfolio in Q4 2025, its #1 holding.
Iron Triangle Partners first reported a position in Charles River Laboratories in Q1 2020 and has held it in 14 quarters since.
582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.